Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Potential Cost of Not Vaccinating against COVID-19 in the US

  • At: PPR 2022 (2022)
  • Type: Poster
  • By: SEO, See-won (Albany College of Pharmacy and Health Sciences)
  • Co-author(s): See-won Seo, Associate Professor, Albany College of Pharmacy and Health Sciences, United States
    Hoai-An Truong, Professor and Director of Public Health, University of Maryland Eastern Shore, United States
    Rajesh Nayak, Associate Professor, St. John's University, United States
    Gretchen Garofoli, Clinical Associate Professor, West Virginia University, United States
    Abby Kahaleh, Tenured Faculty of Clinical & Administrative Sciences , Roosevelt University, United States
    Christine Thompson, Pharmacy Student, Cedarville University, United States

  • Abstract:

    Background: As of April 2022, the COVID-19 global pandemic has resulted in over 6 million deaths globally, and over 81 million cases of COVID-19 in the United States.1

    Purpose: The objective of the presentation is to share estimated direct and indirect costs due to COVID-19 infection juxtaposed with the costs of COVID-19 vaccine administration in the United States.

    Methods: A literature review was conducted to identify potential cost savings from being immunized against COVID-19. The costs of COVID-19 vaccinations, direct costs related to healthcare and types of indirect costs were noted.

    Results: After reviewing over 40 resources, several costs were identified. The cost of COVID-19 vaccine series, as defined by the Centers of Medicare and Medicaid Services (CMS), is currently $40 for single-dose and $40 per dose in a multiple-dose series. It is estimated that the average hospitalization stay of an uninsured inpatient was ~$7000-$10,000 per day.2 The average cost of 12 major metropolitan cities in the United States were estimated for primary care facilities, urgent care facilities, and emergency room visits at $195, $239, $1,425, respectively.3 As of April 2, 2022, 77% of the US have received at least one dose of COVID-19 vaccine and 66% are considered to be fully vaccinated against COVID-19 primary series.4

    Conclusion: According to the data, the cost reduction in healthcare is consequential and cost-effective in vaccinating the population. This analysis contributes to the limited reports of a national cost-benefit analysis.

Last update 4 October 2019

FIP Congresses